Tysabri and PML: How Clinicians Evaluate the Risk in Individual Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Science to Specific Drug Safety

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This page explains how clinicians evaluate that risk, drawing on decades of drug safety research and regulatory oversight. We cover the key factors that go into a PML diagnosis and what the FDA warning means for patients.

Tysabri and PML: A Documented Causal Association

Tysabri (natalizumab) is a monoclonal antibody used primarily in the treatment of multiple sclerosis and Crohn's disease. Its association with progressive multifocal leukoencephalopathy (PML) is a well-documented and serious adverse effect, as reflected in FDA warnings and clinical data. PML is an opportunistic viral infection of the brain caused by the JC virus, which typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA has issued a boxed warning for Tysabri, stating that the drug increases the risk of PML, and that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Evidence and Mechanistic Pathway

Clinical trial data provide evidence of PML occurrence. In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight the variable timeline between exposure and documented harm, with PML occurring after different durations of therapy. The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of immune cells across the blood-brain barrier. This immunosuppressive effect in the central nervous system can allow the JC virus to reactivate and cause PML in susceptible individuals. The presence of anti-JCV antibodies indicates prior exposure to the virus, which is a necessary but not sufficient condition for PML development. Longer treatment duration increases the cumulative immunosuppressive effect, raising the risk.

Risk Anchors and Causation Considerations

Risk anchors for affected patients include the adequacy of warnings and causation considerations. The FDA boxed warning explicitly states that Tysabri increases the risk of PML and outlines the known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, the warning also notes that these factors should be considered in the context of expected benefit, which may lead to variability in risk communication and patient understanding. For patients who develop PML, causation considerations involve evaluating the presence of risk factors, duration of therapy, and any prior immunosuppressant use. The timeline between exposure and harm can range from months to years, as seen in clinical trials where PML occurred after eight doses in one patient and after a median of 120 weeks in others (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Adverse event reports from the FDA FAERS database list fatigue, multiple sclerosis relapse, headache, and gait disturbance as the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most frequently reported events, its severity and high mortality rate make it a critical safety concern. The boxed warning and restricted distribution program aim to mitigate risk, but the occurrence of PML in clinical trials and post-marketing reports underscores the ongoing need for vigilant monitoring. In summary, the evidence establishes a clear causal link between Tysabri and PML, with identified risk factors and a documented timeline of harm. The FDA warnings provide guidance for risk mitigation, but the potential for severe outcomes remains a significant concern for patients and healthcare providers.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning regarding Tysabri and PML?

The FDA has issued a boxed warning for Tysabri (natalizumab) stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection caused by the JC virus. Healthcare professionals are advised to monitor patients for any new signs or symptoms suggestive of PML and to withhold dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three primary risk factors have been identified: the presence of anti-JCV antibodies (indicating prior JC virus exposure), longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How does Tysabri cause PML?

Tysabri is an alpha-4 integrin antagonist that inhibits the migration of immune cells across the blood-brain barrier. This immunosuppressive effect in the central nervous system can allow the JC virus to reactivate and cause PML in susceptible individuals. The presence of anti-JCV antibodies and longer treatment duration increase the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.